356 related articles for article (PubMed ID: 16871222)
1. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight.
Frankenbusch K; Eifinger F; Kribs A; Rengelshauseu J; Roth B
J Perinatol; 2006 Aug; 26(8):511-4. PubMed ID: 16871222
[TBL] [Abstract][Full Text] [Related]
2. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous aspergillosis in an extremely low birth weight preterm.
Erişir-Oygucu S; Akcan AB; Oygür N
Turk J Pediatr; 2009; 51(6):621-3. PubMed ID: 20196401
[TBL] [Abstract][Full Text] [Related]
6. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
7. Combination antifungal therapy with voriconazole for persistent candidemia in very low birth weight neonates.
Turan O; Ergenekon E; Hirfanoğlu IM; Onal EE; Baş VN; Türkyilmaz C; Koç E; Atalay Y
Turk J Pediatr; 2011; 53(1):19-26. PubMed ID: 21534335
[TBL] [Abstract][Full Text] [Related]
8. Neonatal cutaneous disseminated aspergillosis in a preterm extremely-low-birth-weight infant with favourable outcome at 3-year follow-up: a case report.
Manzoni P; Rizzollo S; Monetti C; Carbonara C; Priolo C; Mastretta E; Barberis L; Galletto P; Cigna P; Leonessa ML; Sala U; Gomirato G; Mostert M; Stronati M; Ruffinazzi G; Tzialla C; Jacqz-Aigrain E; Kaguelidou F; Farina D
Early Hum Dev; 2012 May; 88 Suppl 2():S65-8. PubMed ID: 22633518
[TBL] [Abstract][Full Text] [Related]
9. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant.
Klein KC; Blackwood RA
Pediatrics; 2006 Aug; 118(2):e506-8. PubMed ID: 16816005
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
11. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
[TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous aspergillosis in a preterm infant.
Perzigian RW; Faix RG
Am J Perinatol; 1993 Jul; 10(4):269-71. PubMed ID: 8397559
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole for the treatment of disseminated nodular cutaneous aspergillosis in a patient affected by acute myeloid leukemia.
La Nasa G; Littera R; Maccioni A; Ledda A; Vacca A; Contu L
Hematol J; 2004; 5(2):178-80. PubMed ID: 15048069
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole versus amphotericin B for invasive aspergillosis.
Blot F; Edé C; Nitenberg GM
N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12490695
[No Abstract] [Full Text] [Related]
16. [Primary cutaneous aspergillosis complicated with invasive aspergillosis in an extremely preterm infant: case report and literature review].
Stock C; Veyrier M; Magnin-Verschelde S; Duband S; Lavocat MP; Teyssier G; Berthelot P
Arch Pediatr; 2010 Oct; 17(10):1455-9. PubMed ID: 20488684
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
[TBL] [Abstract][Full Text] [Related]
18. An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis.
Chow L; Brown NE; Kunimoto D
Clin Infect Dis; 2002 Nov; 35(9):e106-10. PubMed ID: 12384856
[TBL] [Abstract][Full Text] [Related]
19. Aspergillus fumigatus: a potentially lethal ubiquitous fungus in extremely low birthweight neonates.
Langan EA; Agarwal RP; Subudhi CP; Judge MR
Pediatr Dermatol; 2010; 27(4):403-4. PubMed ID: 20653867
[TBL] [Abstract][Full Text] [Related]
20. Successful management of invasive aspergillosis with voriconazole and amphoteracin B therapy in a patient with acute mycloid leukemia (AML-M2).
Manzoor NF; Azim S; Fadoo Z
J Pak Med Assoc; 2010 Nov; 60(11):977-9. PubMed ID: 21375212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
